Sagent Chairman and CEO Jeff Yordon Inducted Into the UIC Chicago Area Entrepreneurship Hall of Fame
November 07, 2014 09:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) ("Sagent"), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today...
Sagent Pharmaceuticals Reports Third Quarter 2014 Financial Results
November 04, 2014 07:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals Sets Date and Time for Release of Third Quarter 2014 Financial Results
October 24, 2014 16:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Oct. 24, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Three Lots of Ketorolac Tromethamine Injection, USP, 30mg/mL Due to Labeling the Product With the Incorrect Expiration Date
October 03, 2014 12:01 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of three lots of Ketorolac Tromethamine Injection, USP,...
Sagent Pharmaceuticals Announces Acquisition of Omega Laboratories
October 01, 2014 16:10 ET
|
Sagent Pharmaceuticals, Inc.
Expands Sagent's Global Footprint, Product Portfolio and Industry Leading Development Pipeline
Expected to be Immediately Accretive to Cash Earnings
SCHAUMBURG, Ill., Oct. 1, 2014 (GLOBE...
Sagent Pharmaceuticals Announces the Launch of GLYDO(TM) (Lidocaine HCI Jelly USP, 2%)
September 26, 2014 13:41 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Sept. 26, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced the launch of GLYDO™ (lidocaine HCI jelly USP, 2%), Sagent's new branded drug...
Sagent Pharmaceuticals Announces the Introduction of Oxaliplatin Injection, USP
September 23, 2014 16:05 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the introduction of Oxaliplatin Injection, USP, an antineoplastic agent, now in two...
Sagent Pharmaceuticals Announces the Launch of Ketorolac Tromethamine Injection, USP
September 17, 2014 16:30 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Ketorolac Tromethamine Injection, USP, a nonsteroidal anti-inflammatory...
Sagent Pharmaceuticals Announces the Launch of Ibandronate Sodium Injection
September 05, 2014 13:21 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Sept. 5, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Ibandronate Sodium Injection, a bisphosphonate, in a preservative-free,...
Sagent Pharmaceuticals Announces the Reintroduction of Irinotecan Hydrochloride Injection, USP
August 05, 2014 08:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the reintroduction of Irinotecan Hydrochloride Injection, USP, an antineoplastic agent, in...